Company intelligence / Profile preview

NuPulse

Raleigh, North Carolina, United Statesnupulsecv.com ↗

Ownership: Private
Development stage: Phase 3

Overview

NuPulse has developed the Voyage™ and iVAS devices—minimally invasive implantable cardiac assist pumps for patients with advanced or chronic heart failure. The iVAS device has completed an 81-patient feasibility trial across 17 sites with positive results, including zero device thrombosis or major complications and successful discharge of many patients from the hospital. The Voyage is preparing to enter a pivotal trial to support market approval[3][4].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

NuPulse Voyage

Phase 3

Indications: Chronic heart failure

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on NuPulse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuPulse.

Explore the full profile